scholarly journals Hazard rate of tumor recurrence over time: a pooled-analysis of three clinical trials with fluoropyrimidine-based adjuvant chemotherapy for colorectal cancer achieved by the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC)

2016 ◽  
Vol 24 (2) ◽  
pp. 60-61
Author(s):  
Hiromichi Maeda ◽  
Koji Oba ◽  
Chikuma Hamada ◽  
Sotaro Sadahiro ◽  
Toru Aoyama ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Hazard Rate ◽  
Tumor Recurrence ◽  
Multidisciplinary Treatment ◽  
Pooled Analysis ◽  
Over Time

Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

2008 ◽  
Vol 26 (30) ◽  
pp. 4906-4911 ◽  
Author(s):  
Emmanuel Mitry ◽  
Anthony L.A. Fields ◽  
Harry Bleiberg ◽  
Roberto Labianca ◽  
Guillaume Portier ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Progression Free Survival ◽  
Pooled Analysis ◽  
Complete Resection ◽  
Hazard Ratio ◽  
Free Survival ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases

Purpose Adjuvant systemic chemotherapy administered after surgical resection of colorectal cancer metastases may reduce the risk of recurrence and improve survival, but its benefit has never been demonstrated. Two phase III trials (Fédération Francophone de Cancérologie Digestive [FFCD] Trial 9002 and the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada Clinical Trials Group/Gruppo Italiano di Valutazione Interventi in Oncologia [ENG] trial) used a similar design and showed a trend favoring adjuvant chemotherapy, but both had to close prematurely because of slow accrual, thus lacking the statistical power to demonstrate the predefined difference in survival. We report here a pooled analysis based on individual data from these two trials. Patients and Methods After complete resection of colorectal liver or lung metastases, patients were randomly assigned to chemotherapy (CT arm; fluorouracil [FU] 400 mg/m2 administered intravenously [IV] once daily plus dl-leucovorin 200 mg/m2 [FFCD] × 5 days or FU 370 mg/m2 plus l-leucovorin 100 mg/m2 IV × 5 days [ENG] for six cycles at 28-day intervals) or to surgery alone (S arm). Results A total of 278 patients (CT, n = 138; S, n = 140) were included in the pooled analysis. Median progression-free survival was 27.9 months in the CT arm as compared with 18.8 months in the S arm (hazard ratio = 1.32; 95% CI, 1.00 to 1.76; P = .058). Median overall survival was 62.2 months in the CT arm compared with 47.3 months in the S arm (hazard ratio = 1.32; 95% CI, 0.95 to 1.82; P = .095). Adjuvant chemotherapy was independently associated with both progression-free survival and overall survival in multivariable analysis. Conclusion This pooled analysis shows a marginal statistical significance in favor of adjuvant chemotherapy with an FU bolus–based regimen after complete resection of colorectal cancer metastases.

Role of radiofrequency ablation in the treatment of liver metastases from colorectal cancer: Pooled analysis of randomized clinical trials.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14557-e14557
Author(s):  
Fabrizio Drudi ◽  
Emiliano Tamburini ◽  
Manuela Fantini ◽  
Antonio Polselli ◽  
Lucia Stocchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Radiofrequency Ablation ◽  
Liver Metastases ◽  
Randomized Clinical Trials ◽  
Pooled Analysis

Cetuximab or Panitumumab versus Bevacizumab in the treatment of first line RAS wild type colorectal cancer: pooled analysis of randomized clinical trials.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14634-e14634
Author(s):  
Emiliano Tamburini ◽  
Britt Rudnas ◽  
Mario Nicolini ◽  
Stefania Nicoletti ◽  
Manuela Fantini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Pooled Analysis ◽  
Wild Type ◽  
First Line

Efficacy of bolus and infusional 5-FU in elderly and non-elderly patients with metastatic colorectal cancer - a pooled analysis of clinical trials

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 8045-8045 ◽  
Author(s):  
G. Folprecht ◽  
D. Cunningham ◽  
B. Glimelius ◽  
F. Dicostanzo ◽  
J. Wils ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Elderly Patients ◽  
Metastatic Colorectal Cancer ◽  
Pooled Analysis

Temporal trends in receipt of adjuvant chemotherapy for veterans with colorectal cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19171-e19171
Author(s):  
Richard Lewis Martin ◽  
Gretchen C. Edwards ◽  
Lauren R. Samuels ◽  
Cathy Eng ◽  
Christianne L. Roumie
Keyword(s):  
Colorectal Cancer ◽  
Quality Improvement ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Temporal Trends ◽  
Stage Ii ◽  
Stage Iii ◽  
Health Administration ◽  
Co Morbidity ◽  
Over Time

e19171 Background: For patients with National Comprehensive Cancer Network (NCCN) high risk stage II or stage III colorectal cancer (CRC), adjuvant chemotherapy improves disease free (DFS) and overall survival (OS). Rates of use vary significantly across health care settings. Several demographic and healthcare factors are associated with decreased receipt of chemotherapy; however, few studies have assessed utilization patterns over time. We evaluated receipt of chemotherapy from 2000-2015 among patients treated at a Southeast Regional Veterans Health Administration (VHA) facility to determine local targets for quality improvement initiatives. Methods: We reviewed 1,107 electronic medical records of patients undergoing colorectal surgery from January 1, 2000 to December 31, 2015 at VHA Tennessee Valley Healthcare System. We included patients with NCCN eligible pathologic high risk stage II (T4/perf, R1, < 12LN, LVI) or stage III CRC and excluded for age ≥80, age ≥75 hospitalized in the prior year with a major co-morbidity, and death or hospice within 30 days of surgery. The primary predictor was year of surgery, partitioned 2000-2005 (N = 60), 2006-2010 (N = 64), 2011-2015 (N = 56) to reflect changes in NCCN guidelines. The primary outcome was receipt of any chemotherapy. Results: Of 1,107 colorectal surgeries, we excluded 623 for non-cancers, 212 for stage I or low-risk stage II cancer, 47 for metastatic disease, and 45 for age, co-morbidity, death, and hospice, yielding a final cohort of 121 colon and 59 rectal cancers. Most patients were male (96%), white (79%), with median age 64 years [Interquartile Range 60, 70]. Overall, 117 of 180 (65%) received chemotherapy with a median time to treatment of 50.5 days [40,64]. Adjusting for known correlates, receipt of chemotherapy decreased over time; 2000-2005 (72%), 2006-2010 (69%), 2011-2015 (53%) p = 0.02. Regardless of CRC stage, more patients declined chemotherapy in 2011-2015 (27%) compared to 2000-2005 (6%) and 2006-2010 (8%) p < 0.01. Conclusions: We identified decreased utilization of adjuvant chemotherapy in a non-elderly veteran cohort, which appeared to be due to patients declining chemotherapy regardless of cancer stage. Understanding patient and provider decisions around adjuvant chemotherapy and evaluating trends outside the VHA may offer important insights to implementing quality improvement measures.

Long-term survival benefits of adjuvant chemotherapy by decreasing incidence of tumor recurrence without delaying relapse in stage III colorectal cancer

2011 ◽  
Vol 26 (10) ◽  
pp. 1329-1338 ◽  
Author(s):  
Wen-Sy Tsai ◽  
Pao-Shiu Hsieh ◽  
Chien-Yuh Yeh ◽  
Jy-Ming Chiang ◽  
Reiping Tang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Tumor Recurrence ◽  
Stage Iii ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document